Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) (EVOLUTION)
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes Mellitus Type 2
Eligibility Criteria
Inclusion Criteria:
Male and female patients meeting all the following criteria will be enrolled in the study:
- Aged between 20 and 75 years old.
- Diagnosis of T2DM according to the criteria of the American Diabetes Association (ADA).
- Not having received treatment with oral hypoglycemic agents or insulin within 12 weeks prior to the screening visit;
- Glycated hemoglobin (HbA1c) levels at the screening visit of 7.5% ≤ HbA1c ≤ 10.5%, after appropriate treatment with diet and physical exercise for ≥ 12 weeks;
- Body mass index (BMI) of 20 kg/m2 ≤ BMI ≤ 40 kg/m2 at the screening visit.
- Signing the Informed Consent Form (ICF) before the performance of any study procedure.
Exclusion Criteria:
- Patients meeting at least one of the following criteria will be excluded from the study:
- Fasting blood glucose values > 300 mg/dL with severe clinical manifestations present (significant loss weight, severe symptoms and/or ketonuria).
- Current participation in weight loss programs, with or without anti-obesity drugs use.
- Presence of heart failure functional class III or IV according to the New York Heart Association (NYHA).
- Presence of symptomatic liver or gall bladder disease.
- History of myocardial infarction, transient ischemic attack or coronary angioplasty within 6 months prior to the screening visit.
- History of gastrointestinal resection.
- Estimated creatinine clearance (Cockroft and Gault formula) < 60 mL/min.
- Serum ALT and/or AST level ≥ 2.5 x upper normal limit.
- Serum CPK level ≥ 3 x upper normal limit.
- Fasting triglycerides > 400 mg/dL.
- History of major skin allergy.
- Use of corticosteroids within 3 months prior to the screening visit.
- Concomitant treatment with warfarin, dicoumarinic agents or digoxin.
Concomitant use of drugs or foods that interfere with the CYP3A4 pathway of liver metabolism including, but not limited to:
- Inhibitors: antibacterial agents (erythromycin), antifungals (itraconazole, ketoconazole), antivirals (ritonavir, saquinavir, amprenavir, indinavir, nelfinavir), H2 receptor antagonists (cimetidine) and grapefruit juice;
- Inducers: dexamethasone, rifampin and anticonvulsants (phenytoin, phenobarbital, carbamazepine)
- History of untreated or uncontrolled thyroid disorder.
- History of drugs of abuse or moderate/heavy alcohol consumption within 2 months prior to screening.
- Presence of severe or uncontrolled diseases.
- Presence of pregnancy or breastfeeding.
- Women of childbearing potential who do not agree to use a proven effective contraceptive method, unless they are surgically sterile or declare being expressly exempt of pregnancy risk for not engaging in sexual practices or for engaging in them in a non-reproductive manner.
- Participation in a clinical trial protocol within the previous 12 months unless, at the investigator's discretion, his or her participation may imply a direct benefit for the participant.
- Presence of any condition which, at the investigator's discretion, may render the patient inadequate for study participation.
Sites / Locations
- Centro de Estudos em Diabetes e Hipertensão
- Hospital Universitário João de Barros Barreto - HUJBB
- CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda
- Centro de Pesquisa Clínica em Diabetes - UNIFESP
- CEPIC - Centro Paulista de Investigação Clínica
- Clinica de Endocrinologia e Metabologia LTDA
- CPCLIN - Centro de Pesquisas Clinicas LTDA
- HCFMUSP
- IMA - Instituto de Pesquisa Clínica e Medicina Avançada Ltda
- IPEC - Instituto de Pesquisa Clínica Ltda
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Active Comparator
Evogliptin 2.5mg+Placebo Sitagliptin
Evogliptin 5.0mg+Placebo Sitagliptin
Evogliptin 10.0mg+Placebo Sitagliptin
Sitagliptin 100mg+Placebo Evogliptin
Evogliptin (EVO) will be administered orally at a daily dose of: 2.5 mg. The participants randomized to this group will receive 1 tablet daily of EVO 2.5 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
Evogliptin (EVO) will be administered orally at a daily dose of: 5.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 5.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
Evogliptin (EVO) will be administered orally at a daily dose of: 10.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 10.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.